Literature DB >> 31521687

Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP.

Shawn H Reginauld1, Valentina Cannone2, Seethalakshmi Iyer1, Christopher Scott3, Kent Bailey3, Jacob Schaefer1, Yang Chen1, S Jeson Sangaralingham4, John C Burnett5.   

Abstract

OBJECTIVES: This study investigated the differential regulation of circulating atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in patients with acute decompensated heart failure (ADHF) and tested the hypothesis that a relative deficiency of ANP exists in a subgroup of patients with ADHF.
BACKGROUND: The endocrine heart releases the cardiac hormones ANP and BNP, which play a key role in cardiovascular (CV), renal, and metabolic homeostasis. In heart failure (HF), both plasma ANP and BNP are increased as a compensatory homeostatic response to myocardial overload.
METHODS: ANP and BNP concentrations were measured in a small group of patients with ADHF (n = 112). To support this study's goal, a total of 129 healthy subjects were prospectively recruited to establish contemporary normal values for ANP and BNP. Plasma 3',5'cyclic guanosine monophosphate (cGMP), ejection fraction (EF), and body mass index (BMI) were measured in these subjects.
RESULTS: In cases of ADHF, 74% of patients showed elevated ANP and BNP. Importantly, 26% of patients were characterized as having normal ANP (21% of this subgroup had normal ANP and elevated BNP). Cyclic GMP was lowest in the ADHF group with normal levels of ANP (p < 0.001), whereas BMI and EF were inversely related to ANP levels (p = 0.003).
CONCLUSIONS: Among a subgroup of patients hospitalized with ADHF, the presence of an ANP deficiency is consistent with a differential regulation of ANP and BNP and suggests the existence of a potentially compromised compensatory cardiac endocrine response. These findings have implications for the pathophysiology, diagnostics, and therapeutics of human HF.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute decompensated heart failure; atrial natriuretic peptide; atrial natriuretic peptide deficiency; natriuretic peptide

Mesh:

Substances:

Year:  2019        PMID: 31521687      PMCID: PMC6778016          DOI: 10.1016/j.jchf.2019.05.012

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.544


  34 in total

Review 1.  Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Authors:  Massimo Volpe; Speranza Rubattu; John Burnett
Journal:  Eur Heart J       Date:  2013-11-13       Impact factor: 29.983

2.  Natriuretic Peptide Deficiency-When There Is Too Little of a Good Thing.

Authors:  Thomas J Wang
Journal:  JAMA Cardiol       Date:  2018-01-01       Impact factor: 14.676

3.  Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides.

Authors:  A L Steiner; C W Parker; D M Kipnis
Journal:  J Biol Chem       Date:  1972-02-25       Impact factor: 5.157

4.  Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP.

Authors:  Fima Macheret; Denise Heublein; Lisa C Costello-Boerrigter; Guido Boerrigter; Paul McKie; Diego Bellavia; Sarah Mangiafico; Yasuhiro Ikeda; Kent Bailey; Christopher G Scott; Sharon Sandberg; Horng H Chen; Lorenzo Malatino; Margaret M Redfield; Richard Rodeheffer; John Burnett; Alessandro Cataliotti
Journal:  J Am Coll Cardiol       Date:  2012-10-16       Impact factor: 24.094

5.  B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Authors:  Peder Langeland Myhre; Muthiah Vaduganathan; Brian Claggett; Milton Packer; Akshay S Desai; Jean L Rouleau; Michael R Zile; Karl Swedberg; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2019-03-04       Impact factor: 24.094

6.  Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men.

Authors:  Camilla L Asferg; Søren J Nielsen; Ulrik B Andersen; Allan Linneberg; Daniel V Møller; Paula L Hedley; Michael Christiansen; Jens P Goetze; Murray Esler; Jørgen L Jeppesen
Journal:  Hypertension       Date:  2013-05-13       Impact factor: 10.190

7.  Atrial natriuretic peptide elevation in congestive heart failure in the human.

Authors:  J C Burnett; P C Kao; D C Hu; D W Heser; D Heublein; J P Granger; T J Opgenorth; G S Reeder
Journal:  Science       Date:  1986-03-07       Impact factor: 47.728

8.  Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.

Authors:  S Suga; K Nakao; K Hosoda; M Mukoyama; Y Ogawa; G Shirakami; H Arai; Y Saito; Y Kambayashi; K Inouye
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

Review 9.  Molecular Physiology of Membrane Guanylyl Cyclase Receptors.

Authors:  Michaela Kuhn
Journal:  Physiol Rev       Date:  2016-04       Impact factor: 37.312

10.  Structural substrate conditions required for neutral endopeptidase-mediated natriuretic Peptide degradation.

Authors:  Kristin Pankow; Anja Schwiebs; Matthias Becker; Wolf-Eberhard Siems; Gerd Krause; Thomas Walther
Journal:  J Mol Biol       Date:  2009-08-15       Impact factor: 5.469

View more
  11 in total

Review 1.  Atrial Natriuretic Peptide, Heart Failure and the Heart as an Endocrine Organ.

Authors:  John C Burnett
Journal:  Clin Chem       Date:  2019-07-30       Impact factor: 8.327

2.  Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators.

Authors:  S Jeson Sangaralingham; Kanupriya Whig; Satyamaheshwar Peddibhotla; R Jason Kirby; Hampton E Sessions; Patrick R Maloney; Paul M Hershberger; Heather Mose-Yates; Becky L Hood; Stefan Vasile; Shuchong Pan; Ye Zheng; Siobhan Malany; John C Burnett
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-28       Impact factor: 12.779

3.  Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO.

Authors:  Andrea de la Fuente-Alonso; Marta Toral; Alvaro Alfayate; María Jesús Ruiz-Rodríguez; Elena Bonzón-Kulichenko; Gisela Teixido-Tura; Sara Martínez-Martínez; María José Méndez-Olivares; Dolores López-Maderuelo; Ileana González-Valdés; Eusebio Garcia-Izquierdo; Susana Mingo; Carlos E Martín; Laura Muiño-Mosquera; Julie De Backer; J Francisco Nistal; Alberto Forteza; Arturo Evangelista; Jesús Vázquez; Miguel R Campanero; Juan Miguel Redondo
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

4.  Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy.

Authors:  Shingo Matsumoto; Gaku Nakazawa; Yohei Ohno; Mai Ishihara; Katsuaki Sakai; Norihito Nakamura; Tsutomu Murakami; Makoto Natsumeda; Takayuki Kabuki; Atsushi Shibata; Keisuke Kida; Masaaki Konishi; Shunsuke Ishii; Takanori Ikeda; Yuji Ikari
Journal:  ESC Heart Fail       Date:  2020-10-10

Review 5.  Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.

Authors:  Tomoko Ichiki; Atsushi Jinno; Yoshihisa Tsuji
Journal:  Biology (Basel)       Date:  2022-06-03

6.  Bioactive Peptides and Exercise Modulate the AMPK/SIRT1/PGC-1α/FOXO3 Pathway as a Therapeutic Approach for Hypertensive Rats.

Authors:  Jou-Hsuan Ho; Rathinasamy Baskaran; Ming-Fu Wang; Hong-Siang Yang; Yun-Hsin Lo; Zuhair M Mohammedsaleh; Wan-Teng Lin
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-01

Review 7.  Atrial Natriuretic Peptide31-67: A Novel Therapeutic Factor for Cardiovascular Diseases.

Authors:  Gustavo Jose Justo da Silva; Raffaele Altara; George W Booz; Alessandro Cataliotti
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

8.  Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure.

Authors:  Xiao Ma; Yang Chen; Shawn H Reginauld; Christopher G Scott; Seethalakshmi R Iyer; Jacob J Schaefer; Tomoko Ichiki; Horng H Chen; Andrew D Rule; John C Burnett; S Jeson Sangaralingham
Journal:  JACC Heart Fail       Date:  2021-07-07       Impact factor: 12.544

9.  Cardiac natriuretic peptide deficiency sensitizes the heart to stress-induced ventricular arrhythmias via impaired CREB signalling.

Authors:  Eric J Hall; Soumojit Pal; Michael S Glennon; Puneeth Shridhar; Sidney L Satterfield; Beth Weber; Qinkun Zhang; Guy Salama; Hind Lal; Jason R Becker
Journal:  Cardiovasc Res       Date:  2022-07-20       Impact factor: 13.081

Review 10.  Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology.

Authors:  Alexandra Petraina; Cristian Nogales; Thomas Krahn; Hermann Mucke; Thomas F Lüscher; Rodolphe Fischmeister; David A Kass; John C Burnett; Adrian J Hobbs; Harald H H W Schmidt
Journal:  Cardiovasc Res       Date:  2022-07-20       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.